Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Acquisition Battle Intensifies for Jamf Holding

Dieter Jaworski by Dieter Jaworski
November 13, 2025
in Analysis, Earnings, Mergers & Acquisitions, Tech & Software
0
Jamf Holding Stock
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

The proposed acquisition of Jamf Holding by Francisco Partners has entered a contentious phase, creating uncertainty for shareholders. While the company demonstrated robust quarterly performance, a newly launched shareholder investigation is challenging the adequacy of the $13.05 per share buyout price, raising questions about whether investors deserve greater compensation.

Shareholder Scrutiny Emerges

In a significant midweek development, legal firm Bleichmar Fonti & Auld LLP announced it would examine the board of directors’ handling of the acquisition. The central issue under review is whether the proposed purchase price fairly values Jamf’s equity. Although the offer represents a 50% premium over the three-month average stock price preceding the announcement, several market observers believe the company warrants substantially higher valuation.

Both Needham and Citizens JMP Securities maintain their buy recommendations with price targets ranging between $18 and $20 per share. These optimistic assessments stem from Jamf’s accelerated product innovation, including AI-powered forensic software and expanded platform APIs, which continue to drive business expansion. The company recently secured a significant five-year contract with an Ohio-based university consortium, further strengthening its growth trajectory.

Strong Operational Performance Overshadowed

Jamf delivered impressive third-quarter results, though these achievements have been largely overlooked amid acquisition developments. Revenue climbed 15% to $183.5 million, while adjusted earnings per share of $0.25 exceeded market expectations. Annual recurring revenue advanced to $728.6 million, representing 16% year-over-year growth. This solid operational execution underscores sustained demand for Jamf’s Apple device management solutions.

Should investors sell immediately? Or is it worth buying Jamf Holding?

Despite these strong fundamentals, Jamf has withdrawn future earnings guidance and canceled its quarterly earnings conference call since Francisco Partners disclosed its $2.2 billion acquisition proposal in late October. Management attention has shifted entirely toward finalizing the transaction.

Deal Valuation Under Pressure

The critical question for investors remains whether the current offer sufficiently reflects Jamf’s value or if the shareholder investigation might trigger price renegotiations. The company’s robust quarterly performance and positive analyst assessments provide substantial leverage to those arguing for improved terms.

The ultimate resolution hinges on both the shareholder litigation outcome and pending regulatory approvals. The decision regarding Jamf’s future as a publicly traded company is anticipated in the first quarter of 2026, though the final acquisition price may yet increase before the transaction concludes.

Ad

Jamf Holding Stock: Buy or Sell?! New Jamf Holding Analysis from February 8 delivers the answer:

The latest Jamf Holding figures speak for themselves: Urgent action needed for Jamf Holding investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Jamf Holding: Buy or sell? Read more here...

Tags: Jamf Holding
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Next Post
IonQ Stock

IonQ's Quantum Leap: Spectacular Growth Meets Mounting Losses

Blackrock TCP Capital Stock

Blackrock TCP Capital: Navigating Turbulent Waters as Investor Confidence Wanes

Huazhu Stock

H World Group Shares Poised for Strong Quarterly Results

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com